Insights
Search Results
Client Highlights
4.16.26
Wilson Sonsini Advises Terremoto on IP Matters Related to $108 Million Series C
On April 15, 2026, Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, announced the closing of a $108 million Series C financing round. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, and participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management. Wilson Sonsini Goodrich & Rosati advised Terremoto on IP matters related to the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Centessa on IP Matters Related to Acquisition by Lilly
On March 31, 2026, Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Eli Lilly and Company (Lilly), an American multinational pharmaceutical company, to acquire Centessa. Under the terms of the transaction agreement, Lilly will acquire all of the issued and to be issued share capital of Centessa (including the American Depositary Shares (ADSs) representing ordinary shares) for $38.00 in cash per share plus one non-transferrable contingent value right (CVR) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones described below, for total potential aggregate per share consideration of up to $47.00. The upfront cash consideration represents an aggregate equity value of approximately $6.3 billion and the CVR represents an additional potential aggregate equity value of approximately $1.5 billion. Wilson Sonsini Goodrich & Rosati advised Centessa in IP matters related to the transaction.
Client Highlights
3.12.26
Firm Advises Day One on IP Matters Related to $2.5 Billion Acquisition by Servier
On March 6, 2026, Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related to the transaction.
Client Highlights
11.19.25
Wilson Sonsini Advises Day One on IP Matters Related to Acquisition of Mersana
On November 13, 2025, Day One Biopharmaceuticals (Day One), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced it has signed a definitive merger agreement to acquire Mersana Therapeutics (Mersana). Wilson Sonsini Goodrich & Rosati advised Day One on IP due diligence related to the transaction.
Client Highlights
6.21.23
Firm Advises DICE on IP Matters in $2.4 Billion Deal
On June 20, 2023, Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE. DICE is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. Wilson Sonsini Goodrich & Rosati is advising DICE on the transaction.
Client Highlights
10.21.22
Firm Advises DICE Therapeutics on Patent Matters Related to $345 Million Public Offering
On October 17, 2022, DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced the closing of its previously announced upsized underwritten public offering of 9,452,054 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,232,876 additional shares, at a public offering price of $36.50 per share.
Client Highlights
10.27.21
Firm Advises Quanta Therapeutics on IP Matters Related to $60 Million Series C
On October 26, 2021, Quanta Therapeutics, Inc., a privately held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, announced that it has successfully closed a $60 million Series C financing round led by Surveyor Capital (a Citadel company) and Vida Ventures. New investors Longitude Capital and BVF Partners joined existing investors Sofinnova Investments, Logos Capital, AbbVie Ventures, and Vida Ventures in the financing. Wilson Sonsini Goodrich & Rosati provided IP counsel to Quanta in connection with the Series C transaction.
Quanta will use the proceeds from the financing to advance programs targeting RAF1 and KRAS through clinical candidate selection and IND filing to reach initial proof-of-concept. Leveraging a differentiated mechanism targeting the active conformation of RAS, the Quanta team believes their unique approach, with applicability across mutant RAS forms, will circumvent resistance mechanisms experienced with first-generation inhibitors of KRAS G12C.
The Wilson Sonsini patents and innovations team that advised Quanta with respect to the financing was led by Julia Minitti and included Josh Seitz, Luis Perla, Jose Martinez, and Mike Hostetler.
For more information, please see Quanta’s press release.
Quanta will use the proceeds from the financing to advance programs targeting RAF1 and KRAS through clinical candidate selection and IND filing to reach initial proof-of-concept. Leveraging a differentiated mechanism targeting the active conformation of RAS, the Quanta team believes their unique approach, with applicability across mutant RAS forms, will circumvent resistance mechanisms experienced with first-generation inhibitors of KRAS G12C.
The Wilson Sonsini patents and innovations team that advised Quanta with respect to the financing was led by Julia Minitti and included Josh Seitz, Luis Perla, Jose Martinez, and Mike Hostetler.
For more information, please see Quanta’s press release.
Client Highlights
10.26.21
Firm Advises General Atlantic on CinCor Pharma’s $143 Million Series B Financing
On October 12, 2021, CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing was led by General Atlantic, a leading global growth equity firm, with participation from new investors Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, and Sixty Degree Capital, alongside existing investors Sofinnova Investments, Sofinnova Partners, 5AM Ventures and CinRx. Wilson Sonsini Goodrich & Rosati represented General Atlantic on the transaction.
Client Highlights
9.22.21
Wilson Sonsini Represents New Enterprise Associates and Versant Ventures on 858 Therapeutics’ $60 Million Series A Financing
On September 22, 2021, 858 Therapeutics announced the completion of a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management, and Logos Capital. Wilson Sonsini Goodrich & Rosati represented NEA and Versant Ventures on the transaction.
858’s lead programs focus on the emerging fields of RNA modulation and innate immune pathways in cancer and expand upon insights from over 10 years of work by the founders at predecessor companies. Proceeds from the fundraise are being used to develop a portfolio of small molecules directed against novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response. The Series A proceeds will allow the company to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies, expand its team to about 40 people within the next 18 months, and engage leading academic scientists who have made important contributions in the field and can bring specialized know-how to the company.
858’s lead programs focus on the emerging fields of RNA modulation and innate immune pathways in cancer and expand upon insights from over 10 years of work by the founders at predecessor companies. Proceeds from the fundraise are being used to develop a portfolio of small molecules directed against novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response. The Series A proceeds will allow the company to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies, expand its team to about 40 people within the next 18 months, and engage leading academic scientists who have made important contributions in the field and can bring specialized know-how to the company.
Client Highlights
9.21.21
Firm Advises DICE Therapeutics on IP Matters Related to Upsized Initial Public Offering
On September 14, 2021, DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17.00 per share. Wilson Sonsini Goodrich & Rosati advised DICE Therapeutics in IP matters related to the transaction.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by DICE, are expected to be $204 million. The shares began trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “DICE.” BofA Securities, SVB Leerink, and Evercore ISI are acting as joint bookrunning managers for the offering.
The Wilson Sonsini patents and innovations team that advised DICE Therapeutics on IP matters related to the transaction was led by Julia Minitti and included Ying Chen, Luis Perla, and Mike Hostetler.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by DICE, are expected to be $204 million. The shares began trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “DICE.” BofA Securities, SVB Leerink, and Evercore ISI are acting as joint bookrunning managers for the offering.
The Wilson Sonsini patents and innovations team that advised DICE Therapeutics on IP matters related to the transaction was led by Julia Minitti and included Ying Chen, Luis Perla, and Mike Hostetler.
Client Highlights
8.26.21
Wilson Sonsini Advises DiCE Molecules on Patent Matters Related to $60 Million Series C and IPO Filing
On August 25, 2021, DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, filed for a customary $100 million IPO with the SEC, a day after it had announced the completion of its $60 million Series C-1 financing, which was led by RA Capital Management and Sands Capital, with participation from new and existing investors. Proceeds will support DiCE's lead program to build a pipeline of novel oral candidates to treat chronic diseases in immunology and other therapeutic areas.
Client Highlights
2.19.21
Wilson Sonsini Advises General Atlantic on Patent Matters Related to Centessa Pharmaceuticals' Launch and $250 Million Series A
On February 16, 2021, Centessa Pharmaceuticals (Centessa) launched as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. Centessa’s asset-centric R&D model applied at scale has assembled best-in-class or first-in-class assets, each of which is led by specialized teams committed to accelerate development and reshape the traditional drug development process.